Metoprolol Arrow Lab

Metoprolol, the active ingredient in Metoprolol Arrow Lab, is a beta blocker presented as an oral tablet for oral use. It is used to treat hypertension, angina pectoris, heart failure and to improve outcomes after myocardial infarction in adult patients.

GNH USA supplies Metoprolol Arrow Lab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

- Hypertension: lowers blood pressure by reducing cardiac output and inhibiting renin release. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. - Heart failure: improves left‑ventricular function and reduces hospitalization risk. - Post‑myocardial infarction: lowers the chance of recurrent cardiac events and mortality.

Metoprolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Bradycardia (slow heart rate) - Cold extremities - Gastrointestinal upset (nausea, abdominal discomfort) - Headache

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in patients with asthma - Acute heart failure exacerbation - Allergic reactions (rash, angioedema) - Depression or mood changes

Before initiating Metoprolol, clinicians should consider several safety measures.

- Blood pressure monitoring: ensure baseline and periodic measurements. - Cardiac function assessment: evaluate for existing conduction abnormalities. - Asthma or COPD caution: use with care due to potential bronchoconstriction. - Renal impairment adjustment: dose may need modification in reduced kidney function. - Discontinuation warning: avoid abrupt cessation to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metoprolol can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Other beta‑blockers: additive cardiac depression. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of bradycardia and AV block. - Antiarrhythmic agents (class I): heightened conduction disturbances.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Diuretics: can enhance hypotensive response. - Antidepressants (SSRIs, SNRIs): may affect heart rate control. - Antidiabetic drugs: Metoprolol may mask hypoglycemia symptoms. - ACE inhibitors: monitor for excessive blood pressure reduction.